MX352328B - Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. - Google Patents
Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.Info
- Publication number
- MX352328B MX352328B MX2015003139A MX2015003139A MX352328B MX 352328 B MX352328 B MX 352328B MX 2015003139 A MX2015003139 A MX 2015003139A MX 2015003139 A MX2015003139 A MX 2015003139A MX 352328 B MX352328 B MX 352328B
- Authority
- MX
- Mexico
- Prior art keywords
- treating
- methods
- deficiency
- testoterone
- same
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Gynecology & Obstetrics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
Se proporciona una formulación farmacéutica de undecanoato de testosterona. También se proporcionan métodos para tratar una deficiencia de testosterona o sus síntomas con las formulaciones novedosas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2010/030788 WO2011129812A1 (en) | 2010-04-12 | 2010-04-12 | Oral testosterone ester formulations and methods of treating testoterone deficiency comprising same |
Publications (1)
Publication Number | Publication Date |
---|---|
MX352328B true MX352328B (es) | 2017-11-21 |
Family
ID=43074118
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015003139A MX352328B (es) | 2010-04-12 | 2010-04-12 | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. |
MX2012011952A MX2012011952A (es) | 2010-04-12 | 2010-04-12 | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012011952A MX2012011952A (es) | 2010-04-12 | 2010-04-12 | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP2803350B1 (es) |
JP (1) | JP5992397B2 (es) |
KR (2) | KR101460871B1 (es) |
CN (1) | CN102883710B (es) |
AU (1) | AU2010351080B2 (es) |
BR (1) | BR112012025961B1 (es) |
CA (1) | CA2795908C (es) |
DK (1) | DK2558073T3 (es) |
ES (1) | ES2525520T3 (es) |
HK (1) | HK1180593A1 (es) |
IL (1) | IL222315A (es) |
MX (2) | MX352328B (es) |
NZ (1) | NZ602821A (es) |
RU (1) | RU2012142997A (es) |
SG (1) | SG184540A1 (es) |
WO (1) | WO2011129812A1 (es) |
ZA (1) | ZA201207517B (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8492369B2 (en) | 2010-04-12 | 2013-07-23 | Clarus Therapeutics Inc | Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same |
KR101432466B1 (ko) | 2005-04-15 | 2014-08-21 | 클라루스 쎄러퓨틱스, 아이엔씨. | 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물 |
US11304960B2 (en) | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
US20180153904A1 (en) | 2010-11-30 | 2018-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9358241B2 (en) | 2010-11-30 | 2016-06-07 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US9034858B2 (en) | 2010-11-30 | 2015-05-19 | Lipocine Inc. | High-strength testosterone undecanoate compositions |
US20120148675A1 (en) | 2010-12-10 | 2012-06-14 | Basawaraj Chickmath | Testosterone undecanoate compositions |
ES2638981T3 (es) | 2012-12-20 | 2017-10-24 | Solural Pharma ApS | Forma de dosificación oral sólida del derivado de testosterona |
AU2014232911B2 (en) * | 2013-03-15 | 2019-04-04 | Tolmar, Inc. | Methods of treating testosterone deficiency |
ES2749588T3 (es) | 2013-10-07 | 2020-03-23 | Antares Pharma Inc | Modulación de hematocrito mediante inyección de testosterona a chorro asistida por aguja |
BR112016028192A2 (pt) * | 2014-06-17 | 2017-08-22 | Merck Sharp & Dohme | gerritdina g. schoonus-gerritsma |
WO2015193380A2 (en) | 2014-06-19 | 2015-12-23 | Solural Pharma ApS | Solid oral dosage form of lipophilic compounds |
WO2016022936A1 (en) * | 2014-08-07 | 2016-02-11 | Murty Pharmaceuticals, Inc. | An improved oral gastrointestinal dosage form delivery system of cannabinoids and/or standardized marijuana extracts |
ES2877107T3 (es) | 2014-08-28 | 2021-11-16 | Univ Texas | Formulaciones de testosterona y procedimientos de tratamiento con ellas |
US9498485B2 (en) | 2014-08-28 | 2016-11-22 | Lipocine Inc. | Bioavailable solid state (17-β)-hydroxy-4-androsten-3-one esters |
US20170246187A1 (en) | 2014-08-28 | 2017-08-31 | Lipocine Inc. | (17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE |
WO2016049382A1 (en) * | 2014-09-24 | 2016-03-31 | Lipocine Inc. | Compositions and their use in oral dosing regimens |
US20160361322A1 (en) * | 2015-06-15 | 2016-12-15 | Lipocine Inc. | Composition and method for oral delivery of androgen prodrugs |
CA3078723A1 (en) * | 2016-11-28 | 2018-05-31 | Nachiappan Chidambaram | Oral testosterone undecanoate therapy |
WO2018213772A1 (en) * | 2017-05-18 | 2018-11-22 | Clarus Therapeutics, Inc. | Methods of treating testosterone deficiency |
CN108524485A (zh) * | 2018-02-24 | 2018-09-14 | 中山大学 | 一种猴睾酮缺乏模型的建立方法 |
US20200197412A1 (en) * | 2018-12-20 | 2020-06-25 | Clarus Therapeutics, Inc. | Methods of treating testosterone deficiency |
JP7144346B2 (ja) | 2019-03-20 | 2022-09-29 | 日立Geニュークリア・エナジー株式会社 | 遠隔測定システム、および、遠隔測定方法 |
US11564933B2 (en) * | 2019-04-12 | 2023-01-31 | Tolmar, Inc. | Methods of treating testosterone deficiency |
WO2020210501A1 (en) * | 2019-04-12 | 2020-10-15 | Clarus Therapeutics, Inc. | Oral pharmaceutical products and methods of use combining testosterone esters with anti-hypertensive agents |
US20220265678A1 (en) * | 2019-10-30 | 2022-08-25 | Marius Pharmaceuticals Llc | Preferred oral testosterone undecanoate therapy to achieve testosterone replacement treatment |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
GB9608719D0 (en) * | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
DK1189620T3 (da) * | 1999-04-01 | 2004-08-16 | Akzo Nobel Nv | Formulering indeholdende testosteronundecanoat og amerikansk olie |
US20020102301A1 (en) | 2000-01-13 | 2002-08-01 | Joseph Schwarz | Pharmaceutical solid self-emulsifying composition for sustained delivery of biologically active compounds and the process for preparation thereof |
WO2006013369A2 (en) * | 2004-08-04 | 2006-02-09 | Camurus Ab | Compositions forming non-lamellar dispersions |
GB0417388D0 (en) * | 2004-08-04 | 2004-09-08 | Camurus Ab | Composition |
CN101217963A (zh) * | 2005-04-15 | 2008-07-09 | 克劳拉斯医疗有限公司 | 疏水性药物给药系统及含有疏水性药物的组合物 |
KR101432466B1 (ko) * | 2005-04-15 | 2014-08-21 | 클라루스 쎄러퓨틱스, 아이엔씨. | 소수성 약물의 약물전달시스템 및 이를 포함하는 조성물 |
US11304960B2 (en) * | 2009-01-08 | 2022-04-19 | Chandrashekar Giliyar | Steroidal compositions |
-
2010
- 2010-04-12 SG SG2012075305A patent/SG184540A1/en unknown
- 2010-04-12 AU AU2010351080A patent/AU2010351080B2/en active Active
- 2010-04-12 BR BR112012025961-0A patent/BR112012025961B1/pt active IP Right Grant
- 2010-04-12 KR KR1020127027383A patent/KR101460871B1/ko active IP Right Grant
- 2010-04-12 EP EP14179390.1A patent/EP2803350B1/en active Active
- 2010-04-12 MX MX2015003139A patent/MX352328B/es unknown
- 2010-04-12 EP EP10714521.1A patent/EP2558073B1/en active Active
- 2010-04-12 NZ NZ602821A patent/NZ602821A/en unknown
- 2010-04-12 WO PCT/US2010/030788 patent/WO2011129812A1/en active Application Filing
- 2010-04-12 CA CA2795908A patent/CA2795908C/en active Active
- 2010-04-12 ES ES10714521.1T patent/ES2525520T3/es active Active
- 2010-04-12 JP JP2013504871A patent/JP5992397B2/ja active Active
- 2010-04-12 CN CN201080066142.8A patent/CN102883710B/zh active Active
- 2010-04-12 KR KR1020147001158A patent/KR101607034B1/ko active IP Right Grant
- 2010-04-12 RU RU2012142997/15A patent/RU2012142997A/ru unknown
- 2010-04-12 DK DK10714521.1T patent/DK2558073T3/en active
- 2010-04-12 MX MX2012011952A patent/MX2012011952A/es active IP Right Grant
-
2012
- 2012-10-08 ZA ZA2012/07517A patent/ZA201207517B/en unknown
- 2012-10-09 IL IL222315A patent/IL222315A/en active IP Right Grant
-
2013
- 2013-07-05 HK HK13107867.0A patent/HK1180593A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
SG184540A1 (en) | 2012-11-29 |
EP2558073B1 (en) | 2014-09-10 |
EP2558073A1 (en) | 2013-02-20 |
IL222315A (en) | 2017-07-31 |
MX2012011952A (es) | 2013-02-07 |
NZ602821A (en) | 2014-07-25 |
KR101460871B1 (ko) | 2014-11-11 |
AU2010351080B2 (en) | 2014-08-28 |
KR101607034B1 (ko) | 2016-03-28 |
KR20140012215A (ko) | 2014-01-29 |
ES2525520T3 (es) | 2014-12-26 |
BR112012025961A2 (pt) | 2018-05-15 |
IL222315A0 (en) | 2012-12-31 |
ZA201207517B (en) | 2013-06-26 |
RU2012142997A (ru) | 2014-06-20 |
WO2011129812A1 (en) | 2011-10-20 |
BR112012025961B1 (pt) | 2021-06-15 |
HK1180593A1 (en) | 2013-10-25 |
EP2803350A1 (en) | 2014-11-19 |
EP2803350B1 (en) | 2017-09-20 |
KR20130074770A (ko) | 2013-07-04 |
JP2013523880A (ja) | 2013-06-17 |
CN102883710A (zh) | 2013-01-16 |
AU2010351080A1 (en) | 2012-11-01 |
DK2558073T3 (en) | 2014-12-08 |
JP5992397B2 (ja) | 2016-09-14 |
CA2795908A1 (en) | 2011-10-20 |
CA2795908C (en) | 2015-10-13 |
CN102883710B (zh) | 2014-09-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX352328B (es) | Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos. | |
HRP20190368T1 (hr) | Derivati arilmetoksi izoindolina i pripravci koji ih sadrže te postupci njihove uporabe | |
WO2012055567A3 (en) | Use of malononitrilamides in neuropathic pain | |
WO2012030993A3 (en) | Skin compositions and methods of use thereof | |
AU333421S (en) | Showerhead | |
TN2012000465A1 (en) | Derivatives of 1-amino-2-cyclopropylethylboronic acid | |
IL232515A0 (en) | nadph 4 oxidase inhibitors and pharmaceutical preparations containing them | |
EP2528603A4 (en) | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF PAIN AND OTHER INDICATIONS | |
WO2011106297A3 (en) | Compositions and methods for the diagnosis and treatment of tumor | |
IN2014DN07483A (es) | ||
EP2464383A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF FLU | |
PH12014500859A1 (en) | Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof | |
EP2385769A4 (en) | QUICKLY SOLUBLE VITAMIN FORMULATION AND METHOD FOR THEIR USE | |
EP2560614A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD FOR THEIR ADMINISTRATION | |
UY34455A (es) | Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada | |
EP4233915A3 (en) | Modified release formulations of viloxazine | |
WO2008153784A3 (en) | Hydroxybenzyl or hydroxypyranonemethyl esters as tyrosinase inhibitors | |
HK1196765A1 (zh) | 口服睾酮酯製劑以及包含其的治療睾酮缺乏症的方法 | |
IL222642A0 (en) | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives for the treatment of males | |
UA59396U (ru) | Применение композиций нестероидных противовоспалительных средств с кофеином как препаратов с антиэкссудативной активностью | |
WO2011161465A3 (en) | Composition for treatment of skin | |
UA47350U (en) | use of ethyl ester of N-[(2-oxoindolinelyden-3)-2-oxyacetyl]-aaminoacetic acids as nootropic and anxyolitic agent | |
AU334689S (en) | Display stand and trays | |
AU2010903965A0 (en) | Formulation and method for the treatment of timber | |
AU2009901952A0 (en) | Methods and compositions for the promotion of wound healing |